Prne
April 1st, 2009
LUGANO, Switzerland and DUBLIN - Investment in Line With the Government and IDA Strategy for R&D
Helsinn together with the Irish Tánaiste and Minister for Enterprise, Trade and Employment Mary Coughlan TD, today announced, that Helsinn Holding S.A., a privately owned pharmaceutical company, is to establish a Centre-of- excellence in Research and Development for Oral Solid Dosage (OSD) at its Helsinn Birex Pharmaceuticals facility, one of four businesses at its site at Mulhuddart, Dublin. The investment of over EUR13 million which is supported by Government through IDA Ireland is anticipated to create 10 high-value research positions. Helsinn’s core business is the in-licensing of late-stage pharmaceutical compounds in therapeutic niche areas for development and subsequent commercial manufacture and distribution. The company is primarily active in oncology supportive care, anti-inflammatory and gastrointestinal treatments. The investment is part of Helsinn’s strategic decision to strengthen its in-house development capability.
The Tánaiste said, “This investment will establish the Irish operation as the Centre of Knowledge and Learning for OSD products in the Helsinn Group and also the launch site for new products within its portfolio. Strategically it is very significant for the Irish operation, putting it at the core of Helsinn’s R&D activities. The investment is very much in line with the Government and IDA strategy of transformation of existing Irish operations of international companies, particularly into R&D and knowledge-based activities.” Helsinn’s Irish operation was established in 1990, when it acquired Birex Pharmaceuticals in Dublin. To-date Helsinn has invested a total of over EUR55 million in Ireland and continuously invests in its plants in order to maintain high quality and safety, to increase overall production capacity and to offer its partners up-to date products, technologies and services. It now employs a total of 210 people at its four separate businesses - Helsinn Birex Pharmaceuticals, Helsinn Chemicals Ireland and a sales and marketing company, Helsinn Birex Therapeutics with its Ergha Healthcare division. Riccardo Braglia, Chief Executive Officer of the Helsinn Group said, “This new investment in R&D is another important step for the Irish operation and will be of significant benefit for the future of our international business, with the aim of centralising in the new plant any scientific development for Oral Solid Dosage products.”
About Helsinn
Helsinn, a family owned company headquartered in Lugano, Switzerland, was established in 1976. It employs 450 people between its operations in Switzerland, Ireland and USA and supplies its products to 75 countries.
About Helsinn in Ireland
Helsinn has operated in Ireland since 1990 and its Irish manufacturing facilities are EU certified for manufacture of pharmaceutical products and were successfully inspected by the US Food and Drug Administration last year. The companies manufacture and package the group’s products in compliance with EU, US FDA and all major international health and environmental requirements, thus guaranteeing Helsinn’s clients the highest possible assurance of quality and reliability.
Contact: Helsinn Padraig Somers General Manager, Helsinn Birex Pharmaceuticals Tel.: +353-1-8225404 Department of Enterprise Trade and Employment Press Office Tel.: +353-1-6312200 IDA Ireland Brendan Kenny, Press & PR Tel.: +353-87-9036126
Source: Helsinn Healthcare SA
Contact: Helsinn, Padraig Somers, General Manager, Helsinn Birex Pharmaceuticals, Tel.: +353-1-8225404; Department of Enterprise, Trade and Employment Press Office, Tel.: +353-1-6312200; IDA Ireland, Brendan Kenny, Press & PR, Tel.: +353-87-9036126
Filed under Business, European Government, Government and Policy, Health, Health Care / Hospitals, Investors, Joint Ventures, New Products / Services, Pharmaceuticals | Tags: Europe, Government, Helsinn Healthcare SA, Lugano, Switzerlanddublin | Comment Below
Related Press Releases Palonosetron Effectively Prevents Emesis and Nausea Induced by High Dose Chemotherapy in Patients Undergoing Autologous Stem Cell TransplantationSeptember 21st, 2009 BERLIN -
- Single Dose Palonosetron Achieves Optimal Control of Acute Emesis in Patients Receiving Multiday-High Dose Chemotherapy Before Autologous Stem Cell Transplantation. - The Addition of a Second Dose of Palonosetron After 48 Hours Significantly Reduces the Detrimental Impact of Nausea on Daily Activities in This Setting. Helsinn Partners With Eisai for Gelclair in ItalySeptember 14th, 2009 LUGANO, Switzerland - The Swiss pharmaceutical group Helsinn and Eisai Italy, subsidiary of the Japanese pharmaceutical company, have signed a licensing agreement for the commercialization of the medical device Gelclair in Italy. Helsinn is the worldwide licensor of Gelclair, a viscous, concentrated, bioadherent oral gel with a mechanical protective action, which relieves pain by adhering to the mucosal surface of the mouth. New Chief Executive Officer and Vice President Commercial Operations USA at the Helsinn Group's American subsidiary, Helsinn Therapeutics (U.S.) Inc.September 8th, 2009 LUGANO, Switzerland - As part of the Helsinn Group's development strategy, William Mann, PhD, has been appointed as new CEO in the American subsidiary, Helsinn Therapeutics (U.S.) Inc. William Mann, PhD, was already Chief Operating Officer of the recently acquired Helsinn Therapeutics, and has held leadership positions in a Swiss multinational with positions in Business Development and in Research. Supportive Care in Cancer: Palonosetron Recommended 5-HT3 Antagonist for Emesis Prevention by MASCC/ESMOJune 29th, 2009 LUGANO, Switzerland -
- Anticipated at the Rome 2009 MASCC International Symposium the Outcome of the 2009 Joint MASCC (Multinational Association for Supportive Care in Cancer)/ESMO (European Society of Medical Oncology) Antiemetic Guideline Update Meeting New important acknowledgment for palonosetron, the second generation 5-HT3 receptor antagonist for prevention of chemotherapy induced nausea and vomiting (CINV). In April, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology on Antiemesis included palonosetron, as the "preferred" 5-HT3 antagonist in the combined regimen recommended for emesis prevention in patients undergoing highly emetogenic chemotherapy (HEC). Second Generation 5-HT3 Antagonists Open New Perspectives in Emesis PreventionJune 24th, 2009 ROME - The MASCC (Multinational Association of Supportive Care in Cancer) 2009 International Symposium opens today in Rome, Italy - Chemotherapy-induced nausea and vomiting (CINV), treatment of pain, and quality of life in survivors among the key topics of the conference
"Supportive care in cancer is a field of increasing relevance for both oncology patients and clinical research", said Maurizio Tonato, Co-chair of the MASCC 2009 International Symposium, inaugurated in Rome today. Tonato explained how supportive care, in conjunction with anticancer treatments, may significantly increase quality of life in patients especially addressing the most dreaded consequences and complications, including pain and emesis. Helsinn Announces New Plans for its Manufacturing OperationsJune 21st, 2009 LUGANO, Switzerland - Today the Swiss pharmaceutical group Helsinn announced new plans aimed at creating a competitive Manufacturing Organization focused on highly potent compounds, with strong R&D and production capabilities. Both financial investments and a new organization of the manufacturing sites in Ireland and Switzerland are part of this strategy. Single Dose Palonosetron Prevents Emesis Induced by Chemotherapy in Non Hodgkin's Lymphoma PatientsJune 4th, 2009 BERLIN, Germany - Single Dose Palonosetron is Effective and Safe in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients With Aggressive Non-Hodgkin's Lymphomas who Undergo Moderately Emetogenic Chemotherapy
- Data Presented Today at the European Haematology Association Congress in Berlin, Germany
New data presented today at the EHA (European Haematology Association) Congress in Berlin show that a single dose of palonosetron, a second generation 5-HT3 receptor antagonist, is effective and safe in preventing chemotherapy-induced nausea and vomiting (CINV) in patients with aggressive non Hodgkin's lymphoma (NHL), treated with cytotoxic agents. The result comes from a study conducted in Italy on behalf of the Italian Group of Study on Lymphomas (GISL) by a multicentric team coordinated by Dr. Palonosetron "Preferred" 5-HT3 Antagonist for Emesis Prevention in Oncology Patients Receiving Highly Emetogenic ChemotherapyApril 1st, 2009 LUGANO, Switzerland - A new release of the NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines in Oncology on Antiemesis recommends palonosetron as the "preferred" 5-HT3 antagonist in combination with aprepitant and dexamethasone for prevention of emesis in highly emetic risk chemotherapy. Based on the important multicenter study published in The Lancet Oncology by the equipe of Dr. Opening of DAAD Centre of Excellence in South Africa With Nobel Peace Prize Laureate TutuMarch 24th, 2009 BONN, Germany - Training for African Executives in Development Research and Criminal
Justice
On the occasion of the opening ceremony of the South African-German
Centre of Excellence for Development Research and Criminal Justice, due to
take place in Cape Town on April 2, Nobel Peace Prize laureate Bishop Desmond
Tutu will hold a ceremonial speech as the guest of honour. The centre is one
of five centres of excellence which the German Academic Exchange Service
(DAAD) is setting up with the financial backing of Germany's Federal Foreign
Office within the scope of its "Aktion Afrika" (Africa campaign). Palonosetron Warrants Adequate Caloric Intake in Oncology Patients Receiving High Emetogenic ChemotherapyMarch 19th, 2009 ZURICH, Switzerland - A new, innovative study shows that a single dose of palonosetron, the
second generation 5-HT3 antagonist, plus dexamethasone not only prevents
chemotherapy-induced nausea and vomiting (CINV), but also allows adequate
caloric intake in oncology patients. Data presented today at the ESMO
Symposium on Cancer and Nutrition in Zurich, Switzerland
New data presented today at the ESMO (European Society of Medical
Oncology) Symposium on Cancer and Nutrition in Zurich shows that
palonosetron, a second generation 5-HT3 receptor antagonist, warrants
adequate caloric intake in oncology patients receiving high emetogenic
chemotherapy (HEC).
Related News Israel to help Haryana farmers increase farm outputJuly 21st, 2009 CHANDIGARH - Israel will set up two "centres of excellence" in Haryana on an outlay of Rs.15.7 crore to help farmers increase production of fruits and vegetables, the country's ambassador to India Mark Sofer said here Tuesday. Once the centres are operational, farmers will be introduced to the latest mechanised farming techniques developed in Israel. Dublin voted Europe's Friendliest CitySeptember 20th, 2009 LONDON - Dublin has been voted the friendliest city in Europe in a poll of 8,000 people across 16 countries. Adults from countries including America, Canada, Germany, Italy, France and Britain named the Irish capital as their top choice in the survey headed by market research company onepoll. Archaeologists uncover 17th century theatre in DublinAugust 15th, 2009 DUBLIN - An archaeological excavation in Dublin, Ireland, has uncovered the foundations of a 17th century theatre and a number of artefacts from theatrical performances. According to a report by RTE News, the excavation, which ends today, is part of a multi-million euro programme to reinstate the Smock Alley Theatre on its original site. Ireland confirms first case of swine fluMay 3rd, 2009 DUBLIN - Ireland announced its first laboratory-confirmed case of swine flu late Saturday. Tony Holohan, chief medical officer of the Department of Health and Children, said the case was first reported Thursday. Government to set up tea museum in DarjeelingFebruary 25th, 2009 NEW DELHI - In order to support tea production and export, the government is going to set up a tea museum at the hill town of Darjeeling and a tea park at commercial centre Siliguri in West Bengal. 'The tea museum will be set up to showcase the development of the tea industry in India over the last two centuries,' Minister of State for Commerce Jairam Ramesh told the Lok Sabha Tuesday. Now, a cookbook to enable you to taste a dish before you make itAugust 4th, 2009 LONDON - A cookbook that can enable one to taste a dish before it is made is among the winners of the 2009 International Design Excellence Awards (IDEA), which have just been announced. It has been designed by Scott Shim of Ohio State University and Xi Calvin Chen of Purdue University in West Lafayette, Indiana. Tripura tribal woman's effort to revive traditional weaving artMay 23rd, 2009 AGARTALA - A tribal woman makes serious effort to revive the dying tribal art of loin loom weaving of 'Chakma' tribe in Tripura. Traditionally, all tribal communities in Tripura have been weaving their cloth for their ethnic attires. CII preparing report on land acquisition normsApril 7th, 2009 KOLKATA - The Confederation of Indian Industry (CII) is preparing a report on land acquisition norms to help the government come up with a uniform policy, protecting the interests of both the industrial and the agricultural sectors. 'There should be transparent land bank available in every state for the purpose of industrial set-up so that the government can assure of continuous tract of land for industrialisation,' CII president Venu Srinivasan told reporters here Tuesday. GM to drop "Mark of Excellence" logo from its vehiclesAugust 26th, 2009 WASHINGTON - General Motors Co. plans to remove its GM "Mark of Excellence" from all models launched by the company in the future. Shed laid-back attitude to improve education, Sibal asks statesJuly 30th, 2009 NEW DELHI - State governments must give up their "chalta hai" (laid-back) attitude to improve the quality of education to take India to new heights, Human Resource Development (HRD) Minister Kapil Sibal said here Thursday. The minister said there is up to 50 percent shortage of teachers in schools in various states.
|
|
